Trust Company of Vermont’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $49.5K | Buy |
1,009
+290
| +40% | +$13.5K | ﹤0.01% | 566 |
|
|
2025
Q3 | $31K | Buy |
719
+345
| +92% | +$13.5K | ﹤0.01% | 651 |
|
|
2025
Q2 | $14.4K | Sell |
374
-166
| -31% | -$6.34K | ﹤0.01% | 765 |
|
|
2025
Q1 | $20.9K | Buy |
540
+166
| +44% | +$6.08K | ﹤0.01% | 666 |
|
|
2024
Q4 | $12.6K | Hold |
374
| – | – | ﹤0.01% | 742 |
|
|
2024
Q3 | $15.3K | Sell |
374
-145
| -28% | -$5.93K | ﹤0.01% | 699 |
|
|
2024
Q2 | $20K | Hold |
519
| – | – | ﹤0.01% | 612 |
|
|
2024
Q1 | $22.3K | Buy |
519
+364
| +235% | +$15K | ﹤0.01% | 608 |
|
|
2023
Q4 | $5.74K | Sell |
155
-400
| -72% | -$14.4K | ﹤0.01% | 654 |
|
|
2023
Q3 | $20.1K | Hold |
555
| – | – | ﹤0.01% | 568 |
|
|
2023
Q2 | $19.8K | Hold |
555
| – | – | ﹤0.01% | 588 |
|
|
2023
Q1 | $19.7K | Buy |
555
+132
| +31% | +$4.62K | ﹤0.01% | 602 |
|
|
2022
Q4 | $14.9K | Sell |
423
-1,360
| -76% | -$45.3K | ﹤0.01% | 624 |
|
|
2022
Q3 | $52K | Hold |
1,783
| – | – | ﹤0.01% | 483 |
|
|
2022
Q2 | $97K | Buy |
+1,783
| New | +$98.4K | 0.01% | 392 |
|
|
2022
Q1 | – | Sell |
-1,775
| Closed | -$98K | – | 485 |
|
|
2021
Q4 | $98K | Buy |
+1,775
| New | +$92.3K | 0.01% | 403 |
|
|
2021
Q3 | – | Sell |
-1,875
| Closed | -$94K | – | 474 |
|
|
2021
Q2 | $94K | Sell |
1,875
-736
| -28% | -$35.4K | 0.01% | 412 |
|
|
2021
Q1 | $116K | Sell |
2,611
-1,624
| -38% | -$73.7K | 0.01% | 361 |
|
|
2020
Q4 | $195K | Hold |
4,235
| – | – | 0.02% | 296 |
|
|
2020
Q3 | $199K | Buy |
4,235
+20
| +0.5% | +$1K | 0.02% | 277 |
|
|
2020
Q2 | $215K | Sell |
4,215
-878
| -17% | -$45K | 0.02% | 268 |
|
|
2020
Q1 | $241K | Buy |
5,093
+80
| +2% | +$4.27K | 0.02% | 259 |
|
|
2019
Q4 | $295K | Buy |
5,013
+372
| +8% | +$20.7K | 0.02% | 270 |
|
|
2019
Q3 | $248K | Sell |
4,641
-437
| -9% | -$22.5K | 0.02% | 288 |
|
|
2019
Q2 | $254K | Buy |
5,078
+81
| +2% | +$4.06K | 0.02% | 286 |
|
|
2019
Q1 | $261K | Buy |
4,997
+1,084
| +28% | +$54.2K | 0.02% | 278 |
|
|
2018
Q4 | $187K | Sell |
3,913
-590
| -13% | -$29.1K | 0.02% | 305 |
|
|
2018
Q3 | $226K | Buy |
4,503
+240
| +6% | +$12.2K | 0.02% | 305 |
|
|
2018
Q2 | $214K | Sell |
4,263
-447
| -9% | -$22.5K | 0.02% | 309 |
|
|
2018
Q1 | $230K | Sell |
4,710
-520
| -10% | -$24.2K | 0.02% | 295 |
|
|
2017
Q4 | $232K | Sell |
5,230
-2,924
| -36% | -$135K | 0.02% | 303 |
|
|
2017
Q3 | $414K | Sell |
8,154
-4,703
| -37% | -$239K | 0.04% | 231 |
|
|
2017
Q2 | $693K | Sell |
12,857
-890
| -6% | -$47.4K | 0.07% | 196 |
|
|
2017
Q1 | $725K | Buy |
13,747
+2,025
| +17% | +$103K | 0.08% | 179 |
|
|
2016
Q4 | $565K | Sell |
11,722
-106
| -0.9% | -$5.24K | 0.07% | 199 |
|
|
2016
Q3 | $638K | Buy |
11,828
+100
| +0.9% | +$5.48K | 0.08% | 172 |
|
|
2016
Q2 | $635K | Buy |
11,728
+240
| +2% | +$12.6K | 0.08% | 163 |
|
|
2016
Q1 | $583K | Buy |
11,488
+620
| +6% | +$30.9K | 0.08% | 164 |
|
|
2015
Q4 | $548K | Sell |
10,868
-47
| -0.4% | -$2.4K | 0.08% | 167 |
|
|
2015
Q3 | $525K | Buy |
10,915
+793
| +8% | +$41.3K | 0.08% | 165 |
|
|
2015
Q2 | $527K | Sell |
10,122
-104
| -1% | -$5.86K | 0.08% | 170 |
|
|
2015
Q1 | $590K | Sell |
10,226
-3,320
| -25% | -$190K | 0.09% | 162 |
|
|
2014
Q4 | $723K | Buy |
13,546
+716
| +6% | +$40.1K | 0.11% | 158 |
|
|
2014
Q3 | $737K | Sell |
12,830
-488
| -4% | -$29.9K | 0.11% | 150 |
|
|
2014
Q2 | $890K | Buy |
13,318
+1,112
| +9% | +$75.3K | 0.14% | 141 |
|
|
2014
Q1 | $815K | Buy |
12,206
+4,528
| +59% | +$306K | 0.13% | 143 |
|
|
2013
Q4 | $513K | Buy |
7,678
+2,690
| +54% | +$174K | 0.09% | 163 |
|
|
2013
Q3 | $313K | Buy |
4,988
+1,326
| +36% | +$85.4K | 0.06% | 181 |
|
|
2013
Q2 | $229K | Buy |
+3,662
| New | +$232K | 0.04% | 194 |
|
Other funds holding GSK
JEST
Trust Company of Vermont's GSK Position: Q4 2025 in Review
Trust Company of Vermont increased its GSK (GSK) stake by 40% in Q4 2025, buying an estimated $13.5K and bringing the position to 1,009 shares worth $49.5K. The position accounts for ﹤0.01% of the portfolio, ranked #566.
Trust Company of Vermont first reported a position in GSK in Q2 2013 and has held it in 49 quarters since. The position peaked at $890K in Q2 2014. 996 funds tracked by Wall St. Rank hold GSK as of Q4 2025.
- Trust Company of Vermont held 1,009 shares of GSK worth $49.5K as of Q4 2025.
- Trust Company of Vermont bought 290 GSK shares in Q4 2025, an estimated $13.5K.
- GSK made up ﹤0.01% of Trust Company of Vermont's portfolio in Q4 2025, its #566 holding.
- Trust Company of Vermont first reported a position in GSK in Q2 2013 and has held it in 49 quarters since.
- Trust Company of Vermont's GSK position peaked at $890K in Q2 2014.
- 996 funds tracked by Wall St. Rank held GSK as of Q4 2025.
Based on Trust Company of Vermont's 13F filing for Q4 2025, filed 16 Jan 2026.